IgA Nephropathy News and Research

RSS

IgA nephropathy (IgAN), also known as Berger’s disease, is the leading cause of primary glomerulonephritis all over the world. It is autoimmune in origin, characterized by the stimulation of genetically determined formation of concentration of IgA1 with galactose-deficient O-glycans in the hinge-region (Hit 1) in the blood. These stimulate anti-glycan antibody production, followed by binding with the aberrantly glycated IgA1.

Pioneering kidney disease research at Leicester receives a major boost on World Kidney Day

Pioneering research by the University of Leicester into chronic kidney disease has received a major boost on World Kidney Day (10th March 2022) following a generous £1million donation from long-term supporter and kidney health advocate Jimmy Mayer.

10 Mar 2022

Study evaluates the potential benefits of mass dipstick screening to detect hematuria

As the saying goes, "the sooner the better," and such is the case for the detection of kidney and urological diseases. Early detection is key, and may be achieved through the use of a dipstick urine test.

4 Feb 2022

Results of high-impact clinical trials could affect kidney-related medical care

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented online at ASN Kidney Week 2021 November 4–November 7.

7 Nov 2021

Study reports safety, efficacy of targeted treatment for IgA nephropathy

IgA nephropathy (IgAN) is a chronic kidney disease occurring in young adults and is one of the most common reasons for kidney transplantation in this age group.

7 Jun 2021

Repurposed drug for acute lung injury in COVID-19

Now, a new study addresses the possible use of an FDA-approved monoclonal antibody, called fostamatinib, a spleen tyrosine kinase inhibitor (SYK), to reduce the levels of mucin-1, a molecule associated with acute lung injury and acute respiratory distress syndrome (ARDS). People who have severe COVID-19 disease may develop ARDS.

2 Jul 2020

Low socioeconomic status associated with certain kidney diseases

A new study found an inverse association between socioeconomic status and certain kidney diseases. The findings appear in an upcoming issue of CJASN.

20 Feb 2020

UAB researchers find key role for IgG autoantibodies in IgA nephropathy

The most common form of the kidney disease called glomerulonephritis is IgA nephropathy.

24 Sep 2019

Omeros’ OMS721 receives positive opinion from EMA's COMP for treating hematopoietic stem cell transplant

Omeros Corporation announced today that the European Medicines Agency's Committee for Orphan Medicinal Products issued a positive opinion recommending orphan drug designation of OMS721 for treatment in hematopoietic stem cell transplantation.

25 Jul 2018

Worldwide study to examine new treatments for IgA nephropathy

A patient from Birmingham is the first person to be recruited into a new worldwide study to test new treatments for a potentially life-threatening kidney condition called IgA nephropathy.

28 Jun 2018

Omeros’ OMS721 receives orphan drug designation from FDA for treatment of IgA nephropathy

Omeros Corporation today announced that OMS721 has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of Immunoglobulin A (IgA) nephropathy.

4 Aug 2017

Scientists identify genetic clues to chronic kidney disease

Using international genomic studies backed by proof-of-concept cell experiments, researchers have identified two genes that contribute to the chronic kidney disease glomerulonephritis.

16 Mar 2017

Researchers uncover new genetic clues linked to autoimmune kidney disease

Researchers have uncovered new genetic clues to understanding IgA nephropathy (IgAN), or Berger's disease, an autoimmune kidney disease and a common cause of kidney failure.

6 Mar 2017

Researchers discover strong genetic risk factor for IgA nephropathy

An international research collaboration has discovered a strong genetic risk factor for IgA nephropathy (IgAN) - the most common inflammatory kidney disease worldwide - and related renal dysfunction.

14 Jul 2016

Study links alpha-defensin genes to IgA nephropathy risk

A gene which forms part of our body's first line of defence against infection may be associated with an increased risk with a type of kidney disease, research involving academics at The University of Nottingham has discovered.

30 Jun 2016

NEFIGAN Trial of Nefecon for treatment of primary IgA nephropathy meets primary endpoint

Pharmalink AB, a specialty pharma company, today announces that the NEFIGAN Trial of Nefecon for the treatment of primary IgA nephropathy has fully met its primary efficacy endpoint at a planned interim analysis and been stopped early with respect to statistical analysis of the endpoint.

14 Apr 2015

IgA Nephropathy News and Research

Further Reading

Pioneering kidney disease research at Leicester receives a major boost on World Kidney Day

Study evaluates the potential benefits of mass dipstick screening to detect hematuria

Results of high-impact clinical trials could affect kidney-related medical care

Study reports safety, efficacy of targeted treatment for IgA nephropathy

Repurposed drug for acute lung injury in COVID-19

Low socioeconomic status associated with certain kidney diseases

UAB researchers find key role for IgG autoantibodies in IgA nephropathy

Omeros’ OMS721 receives positive opinion from EMA's COMP for treating hematopoietic stem cell transplant

Worldwide study to examine new treatments for IgA nephropathy

Omeros’ OMS721 receives orphan drug designation from FDA for treatment of IgA nephropathy

Scientists identify genetic clues to chronic kidney disease

Researchers uncover new genetic clues linked to autoimmune kidney disease

Researchers discover strong genetic risk factor for IgA nephropathy

Study links alpha-defensin genes to IgA nephropathy risk

NEFIGAN Trial of Nefecon for treatment of primary IgA nephropathy meets primary endpoint

Pharmalink AB acquires anti-inflammatory drug candidate from Synartro AB

Anthera Pharmaceuticals reports net loss of $7.0 million for third quarter 2014

Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

Phase 2 study: Rigel's R348 fails to meet endpoints in patients with dry eye disease

Pharmalink’s core patents for Nefecon issued in United States, Europe, China and Hong Kong

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News